X4 Pharmaceuticals (NASDAQ: XFOR) reported fourth‑quarter and full‑year 2025 results that surpassed analyst expectations. Total revenue for the quarter rose to $2.568 million, up from $1.4 million in Q4 2024, while full‑year revenue reached $35.1 million, a jump from $2.6 million in 2024. The company posted a quarterly loss of $0.22 per share, beating the consensus estimate of $0.36 per share, and a full‑year loss of $1.87 per share, slightly better than the $1.89 per share expected by analysts.
Net product sales climbed to $6.5 million for the year, up from $2.6 million in 2024, reflecting stronger demand for the company’s rare‑disease therapies. License and other revenue from the Norgine out‑licensing agreement contributed $28.6 million, accounting for the bulk of the year‑long revenue increase.
The earnings beat was driven by disciplined cost management and a higher mix of product sales relative to licensing income. While the company still incurred a net loss, the narrower loss per share indicates that operating expenses were kept in line with revenue growth, a positive sign for the company’s financial discipline.
Compared with the same period a year earlier, Q4 2025 revenue grew 83% and the net loss narrowed from $39.8 million in Q4 2024 to $23.9 million. Full‑year 2025 net loss of $79.2 million was a significant improvement over the $37.5 million loss reported in 2024, underscoring the impact of the licensing partnership.
Management reiterated its 2026 guidance, maintaining focus on completing the 4WARD Phase 3 trial for chronic neutropenia and preserving a cash runway through 2028. Executive Chairman Adam Craig said, “Our focus remains on our pivotal 4WARD trial in chronic neutropenia as we execute our strategy to deliver life‑changing therapies to people living with rare blood diseases.” The company also highlighted a positive opinion from the European Medicines Agency, which could pave the way for mavorixafor approval in Europe for WHIM syndrome.
Investors responded positively to the results, citing the earnings beat, the extended cash runway, and the EMA opinion as key drivers of confidence in X4’s ability to advance its pipeline and sustain operations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.